Rights and permissions
About this article
Cite this article
Recombinant EPO a no-go for avoiding transfusion-related adverse events. Inpharma Wkly. 1485, 4 (2005). https://doi.org/10.2165/00128413-200514850-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200514850-00010